ArticleDrug safety2018

Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.

John F Marcinak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.